These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32799457)

  • 21. Light-Responsive Pt(IV) Prodrugs with Controlled Photoactivation and Low Dark Toxicity.
    Spector D; Bubley A; Zharova A; Bykusov V; Skvortsov D; Ipatova D; Erofeev A; Gorelkin P; Vaneev A; Mazur D; Nikitina V; Melnikov M; Pergushov V; Bunin D; Kuzmin V; Kostyukov A; Egorov A; Beloglazkina E; Akasov R; Krasnovskaya O
    ACS Appl Bio Mater; 2024 May; 7(5):3431-3440. PubMed ID: 38697834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity.
    Yao H; Chen S; Deng Z; Tse MK; Matsuda Y; Zhu G
    Inorg Chem; 2020 Aug; 59(16):11823-11833. PubMed ID: 32799491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On the stability of Pt(IV) pro-drugs with haloacetato ligands in the axial positions.
    Wexselblatt E; Raveendran R; Salameh S; Friedman-Ezra A; Yavin E; Gibson D
    Chemistry; 2015 Feb; 21(7):3108-14. PubMed ID: 25529335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs.
    Göschl S; Varbanov HP; Theiner S; Jakupec MA; Galanski MS; Keppler BK
    J Inorg Biochem; 2016 Jul; 160():264-74. PubMed ID: 27055943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxoplatin-Based Pt(IV) Lipoate Complexes and Their Biological Activity.
    Liu X; Barth MC; Cseh K; Kowol CR; Jakupec MA; Keppler BK; Gibson D; Weigand W
    Chem Biodivers; 2022 Oct; 19(10):e202200695. PubMed ID: 36026613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological activity of a series of cisplatin-based aliphatic bis(carboxylato) Pt(IV) prodrugs: how long the organic chain should be?
    Zanellato I; Bonarrigo I; Colangelo D; Gabano E; Ravera M; Alessio M; Osella D
    J Inorg Biochem; 2014 Nov; 140():219-27. PubMed ID: 25171667
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Lee VEY; Lim ZC; Chew SL; Ang WH
    Inorg Chem; 2021 Feb; 60(3):1823-1831. PubMed ID: 33464875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs.
    Ravera M; Gabano E; Zanellato I; Bonarrigo I; Alessio M; Arnesano F; Galliani A; Natile G; Osella D
    J Inorg Biochem; 2015 Sep; 150():1-8. PubMed ID: 26042542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multi-action Pt(IV) anticancer agents; do we understand how they work?
    Gibson D
    J Inorg Biochem; 2019 Feb; 191():77-84. PubMed ID: 30471522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis, characterisation and influence of lipophilicity on cellular accumulation and cytotoxicity of unconventional platinum(iv) prodrugs as potent anticancer agents.
    Deo KM; Sakoff J; Gilbert J; Zhang Y; Aldrich Wright JR
    Dalton Trans; 2019 Nov; 48(46):17228-17240. PubMed ID: 31728483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding the Role of Axial Ligands in Modulating the Biopharmaceutical Outcomes of Cisplatin(IV) Derivatives.
    Date T; Kuche K; Ghadi R; Kumar P; Jain S
    Mol Pharm; 2022 May; 19(5):1325-1337. PubMed ID: 35437994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and investigation of photoactivatable platinum(iv) prodrug complexes of cisplatin.
    Lee VEY; Chin CF; Ang WH
    Dalton Trans; 2019 Jun; 48(21):7388-7393. PubMed ID: 30957798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pt(IV) antitumor prodrugs: dogmas, paradigms, and realities.
    Ravera M; Gabano E; McGlinchey MJ; Osella D
    Dalton Trans; 2022 Feb; 51(6):2121-2134. PubMed ID: 35015025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pt(IV) complexes as prodrugs for cisplatin.
    Shi Y; Liu SA; Kerwood DJ; Goodisman J; Dabrowiak JC
    J Inorg Biochem; 2012 Feb; 107(1):6-14. PubMed ID: 22169035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Facile preparation of mono-, di- and mixed-carboxylato platinum(IV) complexes for versatile anticancer prodrug design.
    Zhang JZ; Bonnitcha P; Wexselblatt E; Klein AV; Najajreh Y; Gibson D; Hambley TW
    Chemistry; 2013 Jan; 19(5):1672-6. PubMed ID: 23255183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
    Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
    Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platinum(IV)-Estramustine Multiaction Prodrugs Are Effective Antiproliferative Agents against Prostate Cancer Cells.
    Karmakar S; Kostrhunova H; Ctvrtlikova T; Novohradsky V; Gibson D; Brabec V
    J Med Chem; 2020 Nov; 63(22):13861-13877. PubMed ID: 33175515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new orally active antitumor 1R,2R-cyclohexanediamine-platinum(IV) complex: trans-(n-valerato)chloro(1R,2R-cyclohexanediamine) (oxalato)platinum(IV).
    Kizu R; Nakanishi T; Hayakawa K; Matsuzawa A; Eriguchi M; Takeda Y; Akiyama N; Tashiro T; Kidani Y
    Cancer Chemother Pharmacol; 1999; 43(2):97-105. PubMed ID: 9923814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tuning the activity of platinum(IV) anticancer complexes through asymmetric acylation.
    Chin CF; Tian Q; Setyawati MI; Fang W; Tan ES; Leong DT; Ang WH
    J Med Chem; 2012 Sep; 55(17):7571-82. PubMed ID: 22876932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression.
    Jin S; Guo Y; Song D; Zhu Z; Zhang Z; Sun Y; Yang T; Guo Z; Wang X
    Inorg Chem; 2019 May; 58(9):6507-6516. PubMed ID: 31013065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.